SeaTown Holdings Pte. Ltd. lifted its stake in Boston Scientific Co. (NYSE:BSX) by 38.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 363,500 shares of the medical equipment provider’s stock after purchasing an additional 101,500 shares during the period. Boston Scientific comprises about 2.9% of SeaTown Holdings Pte. Ltd.’s investment portfolio, making the stock its 13th largest position. SeaTown Holdings Pte. Ltd.’s holdings in Boston Scientific were worth $15,623,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of BSX. Whittier Trust Co. lifted its position in shares of Boston Scientific by 31.5% during the second quarter. Whittier Trust Co. now owns 1,069 shares of the medical equipment provider’s stock valued at $46,000 after buying an additional 256 shares during the last quarter. Winslow Evans & Crocker Inc. lifted its position in shares of Boston Scientific by 28.4% during the second quarter. Winslow Evans & Crocker Inc. now owns 1,220 shares of the medical equipment provider’s stock valued at $54,000 after buying an additional 270 shares during the last quarter. Hanseatic Management Services Inc. lifted its position in shares of Boston Scientific by 1.4% during the second quarter. Hanseatic Management Services Inc. now owns 20,714 shares of the medical equipment provider’s stock valued at $890,000 after buying an additional 288 shares during the last quarter. BB&T Corp lifted its position in shares of Boston Scientific by 0.5% during the second quarter. BB&T Corp now owns 52,968 shares of the medical equipment provider’s stock valued at $2,277,000 after buying an additional 288 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of Boston Scientific by 60.0% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 800 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 90.60% of the company’s stock.

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 1,906 shares of Boston Scientific stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $43.00, for a total value of $81,958.00. Following the completion of the transaction, the executive vice president now directly owns 226,835 shares of the company’s stock, valued at approximately $9,753,905. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Maulik Nanavaty sold 3,038 shares of Boston Scientific stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $36.74, for a total value of $111,616.12. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 60,327 shares of company stock worth $2,466,666. 0.66% of the stock is owned by insiders.

Several brokerages recently commented on BSX. BTIG Research set a $46.00 price objective on shares of Boston Scientific and gave the company a “buy” rating in a research report on Wednesday, July 24th. Canaccord Genuity raised their price target on shares of Boston Scientific from $43.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Leerink Swann set a $50.00 price target on shares of Boston Scientific and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Piper Jaffray Companies set a $50.00 price target on shares of Boston Scientific and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Finally, Raymond James raised their price target on shares of Boston Scientific from $48.00 to $50.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $44.91.

BSX traded up $0.52 on Tuesday, hitting $42.85. The company had a trading volume of 2,648,923 shares, compared to its average volume of 5,790,351. The stock has a market cap of $59.17 billion, a price-to-earnings ratio of 29.15, a P/E/G ratio of 2.59 and a beta of 0.80. Boston Scientific Co. has a 1 year low of $31.56 and a 1 year high of $43.66. The stock’s fifty day simple moving average is $42.51. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.04 and a current ratio of 1.31.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.01. The firm had revenue of $2.63 billion for the quarter, compared to analyst estimates of $2.64 billion. Boston Scientific had a net margin of 13.85% and a return on equity of 23.29%. Boston Scientific’s revenue was up 5.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.41 EPS. On average, equities research analysts predict that Boston Scientific Co. will post 1.56 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Featured Article: What is the Consumer Price Index (CPI)?

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.